Cargando…
Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved me...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Turkish Society of Gastroenterology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081121/ https://www.ncbi.nlm.nih.gov/pubmed/36843300 http://dx.doi.org/10.5152/tjg.2023.22239 |
_version_ | 1785021051277672448 |
---|---|
author | Barba Bernal, Romelia Ferrigno, Bryan Medina Morales, Esli Castro, Cristina M. Goyes, Daniela Trivedi, Hirsh Patwardhan, Vilas R. Bonder, Alan |
author_facet | Barba Bernal, Romelia Ferrigno, Bryan Medina Morales, Esli Castro, Cristina M. Goyes, Daniela Trivedi, Hirsh Patwardhan, Vilas R. Bonder, Alan |
author_sort | Barba Bernal, Romelia |
collection | PubMed |
description | Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-activated receptor agonists have shown promising data supporting their use as disease-modifying therapies. Fibroblast growth factor-19 agonists, farnesoid X receptor agonists, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 3 inhibitors are additional agents under investigation as potential disease-modifying therapy. However, evidence supporting the use of certain novel therapies over others is sparse. There is a need for additional clinical trials as well as research aimed at the underlying pathophysiology of primary biliary cholangitis to discover additional therapeutic targets. |
format | Online Article Text |
id | pubmed-10081121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Turkish Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-100811212023-04-08 Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives Barba Bernal, Romelia Ferrigno, Bryan Medina Morales, Esli Castro, Cristina M. Goyes, Daniela Trivedi, Hirsh Patwardhan, Vilas R. Bonder, Alan Turk J Gastroenterol Review Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-activated receptor agonists have shown promising data supporting their use as disease-modifying therapies. Fibroblast growth factor-19 agonists, farnesoid X receptor agonists, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 3 inhibitors are additional agents under investigation as potential disease-modifying therapy. However, evidence supporting the use of certain novel therapies over others is sparse. There is a need for additional clinical trials as well as research aimed at the underlying pathophysiology of primary biliary cholangitis to discover additional therapeutic targets. Turkish Society of Gastroenterology 2023-02-01 /pmc/articles/PMC10081121/ /pubmed/36843300 http://dx.doi.org/10.5152/tjg.2023.22239 Text en 2023 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Review Barba Bernal, Romelia Ferrigno, Bryan Medina Morales, Esli Castro, Cristina M. Goyes, Daniela Trivedi, Hirsh Patwardhan, Vilas R. Bonder, Alan Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives |
title | Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives |
title_full | Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives |
title_fullStr | Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives |
title_full_unstemmed | Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives |
title_short | Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives |
title_sort | management of primary biliary cholangitis: current treatment and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081121/ https://www.ncbi.nlm.nih.gov/pubmed/36843300 http://dx.doi.org/10.5152/tjg.2023.22239 |
work_keys_str_mv | AT barbabernalromelia managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives AT ferrignobryan managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives AT medinamoralesesli managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives AT castrocristinam managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives AT goyesdaniela managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives AT trivedihirsh managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives AT patwardhanvilasr managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives AT bonderalan managementofprimarybiliarycholangitiscurrenttreatmentandfutureperspectives |